# STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

> **NCT04616339** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 31 (actual)

## Conditions studied

- Overweight and/or Obesity

## Interventions

- **DRUG:** PF-06882961 100 mg

## Key facts

- **NCT ID:** NCT04616339
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2021-07-19
- **Final completion:** 2021-07-19
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04616339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04616339, "STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04616339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*